PRESS RELEASE published on 12/05/2025 at 18:00, 4 months 21 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 5 months 1 day ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 5 months 1 day ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 5 months 15 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 6 months 5 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 6 months 5 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 6 months 20 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 6 months 20 days ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 7 months 1 day ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 7 months 1 day ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
Published on 04/27/2026 at 09:40, 1 hour 56 minutes ago Macau Pass Unveils AI Payment Assistant to Upgrade Local Payment Capabilities
Published on 04/25/2026 at 03:10, 2 days 8 hours ago BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 2 days 13 hours ago Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 2 days 13 hours ago Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 2 days 20 hours ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/27/2026 at 11:11, 24 minutes ago Aroundtown SA: Release of a capital market information
Published on 04/27/2026 at 11:05, 31 minutes ago Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen
Published on 04/27/2026 at 11:00, 36 minutes ago Record international participation and continued German momentum as Nordic Bond market delivers second-strongest Q1 on record
Published on 04/27/2026 at 10:39, 57 minutes ago Original-Research: The Platform Group SE & Co. KGaA (von First Berlin Equity Research GmbH): Buy
Published on 04/27/2026 at 10:05, 1 hour 31 minutes ago TeamViewer Advances Toward Autonomous Endpoint Management: Tia Now Generates Automations From Customers' Own Proven Fixes
Published on 04/24/2026 at 17:45, 2 days 17 hours ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 2 days 18 hours ago Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 3 days 16 hours ago Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 3 days 17 hours ago Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group
